Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1394

1.

Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.

He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q.

World J Gastroenterol. 2013;19(14):2171-8. doi: 10.3748/wjg.v19.i14.2171.

2.

Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.

Chen H, Shen DP, Zhang ZZ, Liu JH, Shen YY, Ni XZ.

World J Gastroenterol. 2015 Feb 14;21(6):1838-44. doi: 10.3748/wjg.v21.i6.1838.

3.

Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma.

Tang P, Huang H, Chang J, Zhao GF, Lu ML, Wang Y.

World J Gastroenterol. 2013 May 7;19(17):2697-703. doi: 10.3748/wjg.v19.i17.2697.

4.

Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer.

Sun XR, Sun Z, Zhu Z, Guan HX, Li CY, Zhang JY, Zhang YN, Zhou H, Zhang HJ, Xu HM, Sun MJ.

World J Gastroenterol. 2015 May 7;21(17):5336-44. doi: 10.3748/wjg.v21.i17.5336.

5.

Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.

He XX, Ding L, Lin Y, Shu M, Wen JM, Xue L.

J Clin Pathol. 2015 May;68(5):374-80. doi: 10.1136/jclinpath-2014-202657. Erratum in: J Clin Pathol. 2015 May;68(5):doi:10.1136/jclinpath-2014-202657corr1.

PMID:
25731189
6.

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer.

Gómez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodríguez-Peralto JL, Hidalgo M, López-Ríos F.

J Clin Pathol. 2012 Aug;65(8):751-7. doi: 10.1136/jclinpath-2012-200774.

7.

Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.

Sato Y, Inokuchi M, Takagi Y, Otsuki S, Fujimori Y, Yanaka Y, Kobayashi K, Higuchi K, Kojima K, Kawano T.

J Clin Pathol. 2015 Oct;68(10):795-801. doi: 10.1136/jclinpath-2015-202987.

PMID:
26043748
8.

Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.

Wang YK, Chen Z, Yun T, Li CY, Jiang B, Lv XX, Chu GH, Wang SN, Yan H, Shi LF.

World J Gastroenterol. 2015 Apr 21;21(15):4680-7. doi: 10.3748/wjg.v21.i15.4680.

9.

HER2 expression and its clinicopathological features in resectable gastric cancer.

Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, Sakai Y.

Gastric Cancer. 2013 Jan;16(1):84-93. doi: 10.1007/s10120-012-0150-9.

PMID:
22410801
10.

Clinicopathologic factors and molecular markers related to lymph node metastasis in early gastric cancer.

Jin EH, Lee DH, Jung SA, Shim KN, Seo JY, Kim N, Shin CM, Yoon H, Jung HC.

World J Gastroenterol. 2015 Jan 14;21(2):571-7. doi: 10.3748/wjg.v21.i2.571.

11.

Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.

Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, Nakazawa M, Nobuoka T, Kawayama M, Mikami M, Matsuno T, Hasegawa T, Hirata K, Imai K, Shinomura Y.

World J Gastroenterol. 2012 Dec 7;18(45):6577-86. doi: 10.3748/wjg.v18.i45.6577.

12.

Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology.

Tsapralis D, Panayiotides I, Peros G, Liakakos T, Karamitopoulou E.

World J Gastroenterol. 2012 Jan 14;18(2):150-5. doi: 10.3748/wjg.v18.i2.150.

13.

Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.

Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.

Arch Pathol Lab Med. 2011 Nov;135(11):1460-5. doi: 10.5858/arpa.2010-0541-OA.

PMID:
22032573
14.

Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy?

Selcukbiricik F, Erdamar S, Buyukunal E, Serrdengecti S, Demirelli F.

Asian Pac J Cancer Prev. 2014;15(24):10607-11.

15.

HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial).

Matsumoto T, Sasako M, Mizusawa J, Hirota S, Ochiai A, Kushima R, Katai H, Tanaka Y, Fukushima N, Nashimoto A, Tsuburaya A; Stomach Cancer Study Group of the Japan Clinical Oncology Group..

Gastric Cancer. 2015 Jul;18(3):467-75. doi: 10.1007/s10120-014-0398-3.

PMID:
24993498
16.

Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.

Al-Momani H, Barnes R, El-Hadi A, Shah R, Lewis WG, Edwards P.

World J Gastroenterol. 2012 Nov 28;18(44):6447-51; discussion p.6450. doi: 10.3748/wjg.v18.i44.6447.

17.

Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.

Im SA, Kim JW, Kim JS, Kim MA, Jordan B, Pickl M, Han SW, Oh DY, Lee HJ, Kim TY, Kim WH, Yang HK, Bang YJ.

Diagn Mol Pathol. 2011 Jun;20(2):94-100. doi: 10.1097/PDM.0b013e3181fc02b7.

PMID:
21532492
18.

Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN.

Eur Urol. 2011 Aug;60(2):350-7. doi: 10.1016/j.eururo.2011.05.035.

PMID:
21640482
19.

Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.

Yoshida H, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R, Tsuda H.

Virchows Arch. 2014 Aug;465(2):145-54. doi: 10.1007/s00428-014-1597-3.

PMID:
24889042
20.

Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.

Kochi M, Fujii M, Masuda S, Kanamori N, Mihara Y, Funada T, Tamegai H, Watanabe M, Suda H, Takayama T.

Diagn Pathol. 2013 Nov 21;8:191. doi: 10.1186/1746-1596-8-191.

Supplemental Content

Support Center